地塞米松缓释微粒在增生性玻璃体视网膜病变的应用  

Dexamethasone drug delivery system in treating proliferative vitreoretinopathy

作　　者：张皙[1] 张喜梅[1] 蔡文泉[1] 李佩娟[1] 

机构地区：[1]上海市第一人民医院眼科,200080

出　　处：《临床眼科杂志》2003年第1期3-5,共3页Journal of Clinical Ophthalmology

摘　　要：目的　观察含地塞米松 ( DEX)的缓释微粒治疗增生性玻璃体视网膜病变 ( PVR)的临床疗效。方法　9例 ( 9只眼 )视网膜脱离伴 PVR患者进行常规玻璃体视网膜手术 ,并在玻璃体腔内植入 1粒 DEX微粒 (含地塞米松 1m g) ,观察术后反应及视力、PVR发展、DEX的位置及形状变化等。结果　术后炎症反应轻 ,7只眼视网膜复位 ,3只眼后极部视网膜前有增生 ;2只眼视网膜局限性脱离 ,最终 3只眼玻璃体腔内硅油填充。随访视力有 8只眼较术前提高 ( P =0 .0 15 )。 DEX未见对视网膜有不良影响 ,仅在附着处有少量色素吸附 ,4～ 6月后吸收。结论　 DEX抑制 PVR术后炎症反应及较远期作用是安全、有效的 ;Objective To evaluate the clinical efficacy of an intraocular biodegradable polymer dexamethason drug (DEX) in treating proliferative vitreoretinopathy(PVR).Methods Nine patients(9 eyes) with RD and PVR underwent pars plana vitrectomy (PPV) with an intraocular DEX delivery drug system (DEX-DDS) implantation into vitreous cavity.The follow-up early inflammation,visual acuity(VA),PVR development,position and shape change of DEX were observed.Results The early inflammation was slight,retinal attachment in 7 eyes,PVR development in 3 eyes,limited retinal detachment in 2 eyes,silicone oil tampanade in 3 eyes.The follow-up best VA was markedly improved in 8 eyes than before operation (P=0.015).Conclusion DEX-DDS can prevent postoperative PVR and inflammation more safely and effectively.

关 键 词：地塞米松缓释微粒 增生性玻璃体视网膜病变 临床应用 疗效 术后 炎症 

分 类 号：R774.1[医药卫生—眼科] R988.1[医药卫生—临床医学]